Guidelines from professional societies on the LMWH dose for primary thromboprophylaxis in critically ill and acutely ill patients with COVID-19
| Society . | Critically ill patients . | Acutely ill patients . | Postdischarge . |
|---|---|---|---|
| ACCP36 | Prophylactic | Prophylactic | None |
| AC Forum37 | Intermediate | Prophylactic | None |
| ASH38 | Prophylactic | Prophylactic | None |
| ISTH39 | Prophylactic or intermediate | Prophylactic | None or prophylactic |
| SISET40 | Prophylactic | Prophylactic | None |
| Society . | Critically ill patients . | Acutely ill patients . | Postdischarge . |
|---|---|---|---|
| ACCP36 | Prophylactic | Prophylactic | None |
| AC Forum37 | Intermediate | Prophylactic | None |
| ASH38 | Prophylactic | Prophylactic | None |
| ISTH39 | Prophylactic or intermediate | Prophylactic | None or prophylactic |
| SISET40 | Prophylactic | Prophylactic | None |
These guidelines are constantly evolving and updating as the results of ongoing trials become available.
AC, anticoagulation; ISTH, International Society on Thrombosis and Haemostasis; SISET, Società Italiana per lo Studio dell’Emostasi e della Trombosi.